AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 39241211
Drug: Imlunestrant +
RxNorm normalized name: Imlunestrant
DrugBank: Imlunestrant (DB19043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imlunestrant + abemaciclib + aromatase inhibitor (AI) (n = 43)
Trial: 39241341
Drug: Classical massage
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Classical massage (MG)
Trial: 39241904
Drug: Etonogestrel implant
RxNorm normalized name: Etonogestrel Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etonogestrel implant + oral levonorgestrel (LNG)
Trial: 39241904
Drug: 52 mg
RxNorm normalized name: papain 52 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 52 mg levonorgestrel IUD
Trial: 39242054
Drug: Low-dose interleukin-2
RxNorm normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-dose interleukin-2 (IL-2), dosage and duration not specified
Trial: 39242247
Drug: Hypofractionated radiotherapy
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypofractionated radiotherapy with focal boosts (60Gy in 20 fractions, boost dose up to 68Gy)
Trial: 39242497
Drug: 30-day treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30-day treatment with low-molecular weight heparin (dosage not specified)
Trial: 39242497
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment of 5000 IU low-molecular weight heparin daily from surgery until discharge (approximately 10 days)
Trial: 39242497
Drug: 30-day treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30-day treatment with low-molecular weight heparin
Trial: 39242497
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment of 5000 IU low-molecular weight heparin
Trial: 39242499
Drug: Dexmedetomidine nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine nasal spray (30 µg or 50 µg based on body weight)
Trial: 39242499
Drug: Dexmedetomidine nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine nasal spray
Trial: 39242877
Drug: 500 ml
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ml crystalloid fluid bolus (FB)
Trial: 39243031
Drug: CPAP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP treatment with unrestricted mask-access (34 different masks)
Trial: 39243058
Drug: Formulation-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation-based cognitive behavioral therapy (CBT)
Trial: 39243058
Drug: General offender
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General offender treatment program
Trial: 39243264
Drug: T-TEER with
RxNorm normalized name: T-5224
DrugBank: T-5224 (DB05998)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-TEER with the TriClip implant
Trial: 39243311
Drug: Ruxolitinib (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib (35 mg twice daily, days -15 to -10) and decitabine (20 mg/m² daily, days -10 to -5) plus modified busulfan-cyclophosphamide (mBu/Cy) conditioning regimen
Trial: 39243886
Drug: Medium-dose ExPEC10V
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-dose ExPEC10V (n=8)
Trial: 39243886
Drug: High-dose ExPEC10V
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ExPEC10V (n=8)
Trial: 39243886
Drug: Pooled ExPEC10V
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pooled ExPEC10V group (medium- and high-dose)
Trial: 39243886
Drug: ExPEC10V (medium-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ExPEC10V (medium- and high-doses)
Trial: 39243886
Drug: ExPEC10V medium-dose
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ExPEC10V medium-dose
Trial: 39243886
Drug: ExPEC10V high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ExPEC10V high-dose
Trial: 39244209
Drug: Niraparib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niraparib plus Bevacizumab first-line maintenance therapy
Trial: 39244490
Drug: SHJ002 ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHJ002 ophthalmic solution (0.025%, 0.08%, and 0.25%)
Trial: 39244490
Drug: SHJ002 ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHJ002 ophthalmic solution (0.25%)
Trial: 39244532
Drug: SOC + ablative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOC + ablative therapy (SABR preferred)
Trial: 39244532
Drug: SOC palliative-intent
RxNorm normalized name: Various pain palliation radiopharmaceuticals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOC palliative-intent treatments
Trial: 39244595
Drug: TCZ (Tocilizumab)
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: TCZ (Tocilizumab) 8 mg/kg every 4 weeks to week 48
Trial: 39244893
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet treatment (DAPT)
Trial: 39245053
Drug: 10% aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% aqueous povidone-iodine for skin preparation
Trial: 39245053
Drug: 2% alcoholic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% alcoholic chlorhexidine for skin preparation
Trial: 39245055
Drug: mRNA-1012 (pentavalent;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1012 (pentavalent; B/Yamagata replaced with two additional A/H3N2 strains [Newcastle and Hong Kong]) at 50.0 μg
Trial: 39245055
Drug: mRNA-1012 (pentavalent;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1012 (pentavalent; B/Yamagata replaced with two additional A/H3N2 strains [Newcastle and Hong Kong]) at 62.5 μg
Trial: 39245341
Drug: Hybrid combination
RxNorm normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid combination of ProGlide (PP) and Angio-Seal (AS)
Trial: 39245360
Drug: Cemiplimab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cemiplimab (3 mg/kg intravenously every 2 weeks) for groups 1 and 2
Trial: 39245360
Drug: Cemiplimab (350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cemiplimab (350 mg intravenously every 3 weeks) for groups 3 and 6
Trial: 39245360
Drug: Serious treatment-emergent
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serious treatment-emergent adverse events (grade ≥3) for groups 1-3
Trial: 39245360
Drug: Serious treatment-emergent
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serious treatment-emergent adverse events (grade ≥3) for group 6
Trial: 39245584
Drug: Pneumococcal Polysaccharide
RxNorm normalized name: pneumococcal polysaccharides (23)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pneumococcal Polysaccharide vaccine (PPSV23)
Trial: 39245584
Drug: Typhoid Vi
RxNorm normalized name: Typhoid Vi polysaccharide vaccine
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Typhoid Vi Polysaccharide vaccine (Typhim Vi)
Trial: 39245937
Drug: CABA-201 (fully
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CABA-201 (fully human, 4-1BBz anti-CD19-CAR T cell therapy)
Trial: 39246736
Drug: Medication for
RxNorm normalized name: SALICYLIC ACID 10 mg in 1 mL TOPICAL LOTION [Serious Skincare Continuously Clear Acne Medication For Problematic skin Dry Lo Pro All- Over Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication for opioid use disorder
Trial: 39246736
Drug: Mental health
RxNorm normalized name: MENS HEALTH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mental health medication
Trial: 39246931
Drug: 5% lifitegrast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% lifitegrast ophthalmic solution
Trial: 39247686
Drug: Bamlanivimab 700
RxNorm normalized name: bamlanivimab 700 MG in 20 mL Injection (EUA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bamlanivimab 700 mg mAb therapy
Trial: 39248107
Drug: Lovastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin (40 mg) and Minocycline (100 mg) - dual therapy for 12 weeks
Trial: 39248107
Drug: Minocycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline (100 mg) or Lovastatin (40 mg) - monotherapy for 8 weeks
Trial: 39248170
Drug: Guideline-recommended therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-recommended therapy initiated if AF is detected.
Trial: 39249590
Drug: Magaldrate (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magaldrate (800 mg) with sodium alginate (500 mg), sodium bicarbonate (267 mg), and simethicone (120 mg)
Trial: 39249590
Drug: Magaldrate (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magaldrate (800 mg)
Trial: 39249605
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy with cisplatin-based chemoradiotherapy and pembrolizumab (200 mg, IV every 3 weeks for 18 cycles)
Trial: 39249605
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy with cisplatin-based chemoradiotherapy and pembrolizumab
Trial: 39250131
Drug: Nurse-supported self-directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse-supported self-directed cognitive behavioral therapy for insomnia (CBTi) with six weekly phone calls and assigned treatment manual readings.
Trial: 39250131
Drug: Nurse-supported self-directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse-supported self-directed cognitive behavioral therapy for insomnia (CBTi)
Trial: 39250326
Drug: GSK3858279 (monoclonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3858279 (monoclonal antibody against CCL17)
Trial: 39250515
Drug: Resmetirom 100
RxNorm normalized name: resmetirom 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resmetirom 100 mg
Trial: 39250515
Drug: Resmetirom (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resmetirom (80 mg and 100 mg pooled)
Trial: 39250646
Drug: Peer delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peer delivery of oral-fluid HIVST, STISS, and PrEP refills
Trial: 39250708
Drug: Subcutaneous decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous decitabine at 0.3 mg/kg per day for 10 days
Trial: 39250887
Drug: Normobaric hyperoxia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normobaric hyperoxia (NBO) combined with endovascular treatment (EVT), administered with mask oxygen therapy of 10 L/min.
Trial: 39250887
Drug: Sham NBO
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham NBO (1 L/min) combined with endovascular treatment (EVT).
Trial: 39250922
Drug: SGLT2 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SGLT2 inhibitor plus standard-of-care
Trial: 39251366
Drug: TICK-B (colouring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TICK-B (colouring book) and TKTX cream (topical anaesthetic)
Trial: 39251366
Drug: TKTX cream
RxNorm normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TKTX cream (topical anaesthetic)
Trial: 39251447
Drug: Family Meals
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family Meals on Prescription (FMP) combined with lifestyle treatment
Trial: 39251447
Drug: Lifestyle treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifestyle treatment alone (Control)
Trial: 39251616
Drug: Lower volume
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower volume administration and higher vasoactive support (postoperative hemodynamic management)
Trial: 39252657
Drug: Oral testosterone
RxNorm normalized name: testosterone Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral testosterone undecanoate (225 mg twice daily)
Trial: 39252657
Drug: Oral testosterone
RxNorm normalized name: testosterone Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral testosterone undecanoate
Trial: 39252657
Drug: 1.62% topical
RxNorm normalized name: Testosterone 1.62% Topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.62% topical testosterone gel
Trial: 39252865
Drug: Adebrelimab (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adebrelimab (20 mg/kg, D1, Q3W) plus chemotherapy (EP/EC) followed by sequential thoracic radiotherapy (TRT)
Trial: 39252867
Drug: Hexasodium fytate
RxNorm normalized name: Hexasodium fytate
DrugBank: Hexasodium phytate (DB18232)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hexasodium fytate 7 mg/kg
Trial: 39253004
Drug: Attachment-Based Compassion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attachment-Based Compassion Therapy
Trial: 39253004
Drug: Usual treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual treatments (workshops)
Trial: 39253025
Drug: Collaborative Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collaborative Care (CC) intervention, TBI Care, with weekly assessments and an average of 11 out of 12 sessions with a care manager (CM).
Trial: 39253025
Drug: Collaborative Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collaborative Care (CC) intervention, TBI Care.
Trial: 39253712
Drug: hs-cTnT >9.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hs-cTnT >9.6 ng/L (highest category)
Trial: 39253713
Drug: RAS inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAS inhibitors prescribed in patients with periprocedural myocardial injury (197 patients, 70%)
Trial: 39253713
Drug: RAS inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAS inhibitors prescribed in patients without periprocedural myocardial injury (1,251 patients, 71.2%)
Trial: 39254129
Drug: Break Wave
RxNorm normalized name: ELECTRODE GEL,H-WAVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Break Wave lithotripsy (BWL) device, single treatment of 30 minutes at peak negative pressure of 4.5 to 8 MPa.
Trial: 39254129
Drug: Break Wave
RxNorm normalized name: ELECTRODE GEL,H-WAVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Break Wave lithotripsy (BWL) device, after optimal therapy settings determined.
Trial: 39254466
Drug: Long-term oxygen
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term oxygen therapy for 24 hours per day
Trial: 39254466
Drug: Long-term oxygen
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term oxygen therapy for 15 hours per day
Trial: 39254890
Drug: Ritlecitinib 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritlecitinib 30 mg or 50 mg once daily (with or without an initial 4-week 200-mg daily loading dose)
Trial: 39255444
Drug: B7-H3 chimeric
RxNorm normalized name: allogeneic T cells genetically modified to express anti-B7-H3 chimeric antigen receptor (CAR)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B7-H3 chimeric antigen receptor (CAR) T cells at dose level 1 (DL1) 0.5 × 10^6 cells
Trial: 39255444
Drug: B7-H3 chimeric
RxNorm normalized name: allogeneic T cells genetically modified to express anti-B7-H3 chimeric antigen receptor (CAR)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B7-H3 chimeric antigen receptor (CAR) T cells
Trial: 39255534
Drug: Trastuzumab deruxtecan
RxNorm normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab deruxtecan (T-DXd) 5.4 mg/kg intravenously once every 21 days
Trial: 39255587
Drug: mRNA-1345 100
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1345 100 μg
Trial: 39255991
Drug: MK-5475 32
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-5475 32 µg
Trial: 39255991
Drug: MK-5475 100
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-5475 100 µg
Trial: 39255991
Drug: MK-5475 380
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-5475 380 µg
Trial: 39255990
Drug: BI 1291583
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1291583 5 mg
Trial: 39255990
Drug: BI 1291583
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1291583 2.5 mg
Trial: 39255990
Drug: BI 1291583
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1291583 1 mg
Trial: 39256281
Drug: Metallic taste
RxNorm normalized name: Aluminum metal
DrugBank: Aluminium (DB01370)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metallic taste (MT) experienced by patients during treatment
Trial: 39256291
Drug: Etoricoxib 90
RxNorm normalized name: etoricoxib 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 90 mg/tramadol 50 mg (QD for 7 days)
Trial: 39256291
Drug: Paracetamol 975
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 975 mg/tramadol 112.5 mg (TID for 7 days)
Trial: 39256350
Drug: AAV8-RLBP1 gene
RxNorm normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: AAV8-RLBP1 gene therapy
Trial: 39256835
Drug: FFA levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FFA levels ≥ 580 µmol/L
Trial: 39256835
Drug: FFA levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FFA levels < 310 µmol/L
Trial: 39258838
Drug: Liraglutide (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (3.0 mg once daily)
Trial: 39258976
Drug: Enfortumab vedotin
RxNorm normalized name: ENFORTUMAB VEDOTIN
DrugBank: Enfortumab vedotin (DB13007)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enfortumab vedotin administered after chemotherapy and immunotherapy
Trial: 39259542
Drug: Open-label placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label placebo (OLP) - 1-time subcutaneous lumbar saline injection presented as placebo
Trial: 39259550
Drug: Brief cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief cognitive behavioral therapy for inpatients (up to 4 individual sessions)
Trial: 39259550
Drug: Brief cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief cognitive behavioral therapy for inpatients
Trial: 39259562
Drug: Brigimadlin (BI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brigimadlin (BI 907828), oral administration, intermittent dosing schedule
Trial: 39259562
Drug: Brigimadlin (BI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brigimadlin (BI 907828), oral administration
Trial: 39259959
Drug: VR motor-cognitive
RxNorm normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VR motor-cognitive training (VRMCT) - 16 one-hour training sessions delivered twice per week for 8 weeks.
Trial: 39260076
Drug: suvorexant (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suvorexant (10-20 mg)
Trial: 39260392
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (laxative regimens)
Trial: 39260392
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (colostomy, segmental resection, hemicolectomy, subtotal colectomy)
Trial: 39260540
Drug: Gefapixant (45-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefapixant (45-mg twice daily)
Trial: 39260785
Drug: Renin Angiotensin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renin Angiotensin system inhibitors (RASi) therapy
Trial: 39260856
Drug: Second TNF
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Second TNF blocker
Trial: 39261482
Drug: mRNA-1273 third
RxNorm normalized name: MRNA-1273 SARS-COV-2
DrugBank: Moderna COVID-19 Vaccine (DB15654)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1273 third dose
Trial: 39261786
Drug: Healthy diet
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy diet combined with mindfulness cognitive therapy (educational group-based sessions on Mediterranean-type diet and mindfulness principles)
Trial: 39261815
Drug: Exercise training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise training (group and individual) for four months, including pelvic floor muscle training (PFMT) recommended daily
Trial: 39261900
Drug: 6-monthly monitoring
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 6-monthly monitoring of serum neurofilament light chain (sNfL) in addition to usual care (group A)
Trial: 39261900
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care with 6- or 12-monthly visits (group B)
Trial: 39261953
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy to address maladaptive thought patterns and behaviors around social connection
Trial: 39262903
Drug: Shi's manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shi's manual therapy (SMT)